The global injectable drug delivery devices market size is anticipated to reach USD 823.29 billion by 2030. The market is projected to grow at a CAGR of 8.7% from 2024 to 2030. The increase in the number of chronic diseases like diabetes and cancer has fueled the need for injectable drug delivery. Unlike other traditional forms of drug delivery, injectables allow maximum bioavailability of the pharmaceutical drug as it bypasses the first-pass metabolism. With substantial growth in technological advancements, the devices being manufactured and marketed are built so as to cater to the specific needs of the patients.
With the advent of self-injection devices, injectable drugs can be self-administered without the need for medical assistance. A large number of technology-oriented developments have taken place in the biologics market, which further increases the applicability of these injectable devices in the challenging disease areas. Self-injection devices have allowed patients suffering from diabetes to manage insulin levels with auto-injectors, pen-injectors, and needle-free injectors; thus, the homecare segment has been a large grosser in the end-user application.
The major restraints in this market are injuries and infections caused by needles, ambiguities related to regulatory reimbursements, sterility of the injectable drugs, and the preference of other drug delivery systems that possess less toxicity and are easy to administer. Despite these restraints, the market potential for injectable drug delivery products is tremendous with the majority of the key players opting to injectables over other forms of delivery. The injectable drug delivery industry, based on product type is segmented into two sub-types namely self-injection devices and conventional injection devices. Further, on the basis of therapeutic use, the injectable drug delivery industry is segmented into autoimmune disorders, hormonal disorders, oncology, and others.
The injectable drug delivery industry by end-user application is categorized into hospitals, home care settings, and others including research establishments, diagnostics, and clinical laboratories.
This product will be delivered within 1-3 business days.
With the advent of self-injection devices, injectable drugs can be self-administered without the need for medical assistance. A large number of technology-oriented developments have taken place in the biologics market, which further increases the applicability of these injectable devices in the challenging disease areas. Self-injection devices have allowed patients suffering from diabetes to manage insulin levels with auto-injectors, pen-injectors, and needle-free injectors; thus, the homecare segment has been a large grosser in the end-user application.
The major restraints in this market are injuries and infections caused by needles, ambiguities related to regulatory reimbursements, sterility of the injectable drugs, and the preference of other drug delivery systems that possess less toxicity and are easy to administer. Despite these restraints, the market potential for injectable drug delivery products is tremendous with the majority of the key players opting to injectables over other forms of delivery. The injectable drug delivery industry, based on product type is segmented into two sub-types namely self-injection devices and conventional injection devices. Further, on the basis of therapeutic use, the injectable drug delivery industry is segmented into autoimmune disorders, hormonal disorders, oncology, and others.
The injectable drug delivery industry by end-user application is categorized into hospitals, home care settings, and others including research establishments, diagnostics, and clinical laboratories.
Injectable Drug Delivery Devices Market Report Highlights
- Oncology is anticipated to witness the fastest CAGR of 9.3% over the forecast period. This is due to the growing incidence of cancer globally and the evolution of targeted therapies.
- Hospitals dominated the market with 53.2% share in 2023. Hospitals are increasingly adopting advanced injectable devices due to their ability to provide rapid therapeutic effects, which is crucial in emergency care and critical situations.
- North America injectable drug delivery devices market dominated with 40.5% market share in 2023. North America has a significant population with chronic diseases such as diabetes, cancer, and autoimmune disorders.
The leading players in the Injectable Drug Delivery Devices market include:
- Baxter
- Schott AG
- BD
- Eli Lilly and Company
- Terumo Corporation
- Elcam Medical
- Unilife Corporation
- Ypsomed AG
- Gerresheimer AG
- Sanofi
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Injectable Drug Delivery Devices Market Variables, Trends, & Scope
Chapter 4. Injectable Drug Delivery Devices Market: Product Estimates & Trend Analysis
Chapter 5. Injectable Drug Delivery Devices Market: Therapeutic Use Estimates & Trend Analysis
Chapter 6. Injectable Drug Delivery Devices Market: End Use Estimates & Trend Analysis
Chapter 7. Injectable Drug Delivery Devices Market: Regional Estimates & Trend Analysis
Chapter 8. Competitive Landscape
Companies Mentioned
The leading players in the Injectable Drug Delivery Devices market include:- Baxter
- Schott AG
- BD
- Eli Lilly and Company
- Terumo Corporation
- Elcam Medical
- Unilife Corporation
- Ypsomed AG
- Gerresheimer AG
- Sanofi
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 100 |
| Published | September 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 467.53 Billion |
| Forecasted Market Value ( USD | $ 823.29 Billion |
| Compound Annual Growth Rate | 8.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
